Top Page
Control Bionics Ltd.
(Sydney:CBL)
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Control Bionics Ltd. Business Overview & Revenue Model
Control Bionics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 4.11M | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.14M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.11M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 8.23M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 672.66K | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 435.40K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.72M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 5.51M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.57M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.27M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -744.78K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 4.63M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Control Bionics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
45 Neutral | €36.47M | -6.73 | -513.22% | ― | -34.06% | 75.47% | |
43 Neutral | AU$21.87M | -3.51 | -58.27% | ― | -7.20% | 28.70% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
38 Underperform | AU$5.67M | -4.19 | ― | ― | ― | -55.00% | |
37 Underperform | AU$8.67M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Control Bionics Ltd. Corporate Events
Control Bionics Limited reported a strong first quarter for FY26, with a significant increase in revenue and cash receipts. The company is advancing its distribution strategy for the NeuroNode and expanding its reimbursement coverage in the US, covering over 70% of the population. The NeuroStrip is gaining traction in sports performance and rehabilitation sectors in the US and Australia, with manufacturing scaling up to meet demand. The company also successfully raised capital and received an R&D tax refund, positioning itself for further growth and expansion.
Control Bionics Limited has successfully raised $0.6 million through a shortfall placement, supported by both new and existing shareholders. The funds will be used to enhance the company’s commercialization efforts in neurotechnology, particularly in the sports and rehabilitation markets, strengthening its position in these emerging sectors.
Control Bionics Ltd. has announced its 2025 Annual General Meeting, which will take place on November 25, 2025, in Sydney. The company is emphasizing electronic distribution of meeting notices and proxy forms, encouraging shareholders to participate in voting even if they cannot attend in person. This move highlights Control Bionics’ commitment to engaging its stakeholders through digital means, potentially increasing shareholder participation and streamlining communication.
Control Bionics Ltd. has announced its 2025 Annual General Meeting, scheduled for November 25, 2025, in Sydney. The meeting will address several key resolutions, including the adoption of the remuneration report, re-election of directors, approval of options issuance, and ratification of previous share issues. These resolutions are crucial for the company’s governance and strategic direction, potentially impacting its operational capabilities and shareholder value.
Control Bionics Limited has announced a change in the director’s interest, with Director Stephanie Phillips acquiring 30,000 ordinary shares through a rights issue entitlement. This acquisition reflects an increase in her direct shareholding, which may indicate confidence in the company’s future performance and could influence stakeholder perceptions positively.
Control Bionics Limited has announced a change in the director’s interest, specifically involving Jeremy Steele, who has increased his indirect interest in the company by acquiring 1,142,857 ordinary shares through J Steele Investment Corporation Pty Ltd. This acquisition, valued at $40,000, reflects a strategic move to strengthen his stake in the company, potentially signaling confidence in the company’s future prospects and stability. The impact of this change may influence stakeholder perceptions and market positioning, as it highlights the director’s commitment to the company’s growth and development.
Control Bionics Limited has announced the quotation of 32,874,567 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 17, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial standing and visibility in the market, potentially benefiting stakeholders by increasing the liquidity and marketability of its shares.
Control Bionics Ltd. has announced the quotation of 8,852,473 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 17, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital to support its operations and growth strategies.
Control Bionics Limited has successfully raised approximately $1.46 million through a Non-Renounceable Rights Issue, with plans to issue additional shares to cover the shortfall. This capital injection provides the company with financial flexibility to pursue its business objectives, enhancing its position in the medical device industry and potentially benefiting stakeholders by supporting growth and innovation.
Control Bionics Ltd. announced the completion of an equity raising initiative through a non-renounceable rights issue, aiming to issue up to 58,922,220 shares to raise approximately $2,062,278. This move is designed to strengthen the company’s financial position without materially affecting its control structure, provided shareholders subscribe to their entitlements. The outcome of this offer could influence the company’s control dynamics, particularly if significant shareholders fully subscribe and others do not, potentially increasing their influence over the company.
Control Bionics Ltd. has addressed inquiries from the Australian Securities Exchange regarding its recent financial disclosures. The company reported a consolidated revenue of $6,144,907 and a loss of $6,108,667 for the fiscal year ending June 30, 2025. Despite the financial loss, Control Bionics maintains compliance with relevant listing rules and regulations, ensuring transparency and accountability to its stakeholders.
Control Bionics Ltd. has announced updates to its corporate governance structure, highlighting the expertise and diverse backgrounds of its board members. The appointments of accomplished professionals in neurology, anaesthesia, and corporate management are expected to strengthen the company’s strategic direction and innovation in the medtech industry, potentially benefiting stakeholders by enhancing product development and market expansion.
Control Bionics Limited has released its corporate governance statement for the financial year ending June 30, 2025, which adheres to the ASX Corporate Governance Council’s principles and recommendations. The statement, approved by the board, is available on the company’s website and outlines the extent to which the company has followed these recommendations, providing transparency and accountability to stakeholders.
Control Bionics Ltd. has released its annual report for the year ending June 30, 2025, detailing the company’s financial performance and strategic direction. The report provides insights into the company’s operations, highlighting its commitment to enhancing its product offerings and market presence. This announcement is significant for stakeholders as it outlines the company’s financial health and future growth prospects, reinforcing its position in the assistive technology sector.
Control Bionics Ltd. announced an update regarding their proposed issue of securities, confirming that fractional entitlements to new shares will be rounded up to the nearest whole share. This update is part of a non-renounceable pro-rata issue, which may impact the company’s capital structure and shareholder value, potentially affecting its market positioning and investor relations.
Control Bionics Ltd. has announced a 1-for-5 non-renounceable rights issue to raise up to approximately $2.062 million. The funds will support the company’s growth initiatives, particularly the commercial rollout of NeuroStrip and expansion of the NeuroNode strategy. The company is negotiating distribution partnerships and conducting rehabilitation trials, with positive feedback and expected customer contracts by the end of 2025. The rights issue is partially underwritten, and the company aims to enhance its operational capacity and meet anticipated demand through targeted investments.
Control Bionics Limited reported a 14.84% increase in revenues to $6,144,907 for the year ending June 30, 2025, despite a 3.30% rise in losses, totaling $6,108,667. The company did not declare any dividends, and its net tangible assets per ordinary security decreased from 0.93 cents to 0.49 cents. The financial statements highlight a material uncertainty regarding the company’s ability to continue as a going concern, which may impact stakeholders’ confidence.
Control Bionics Ltd. announced an equity raising initiative involving a non-renounceable rights issue to raise $2,062,278 through the issuance of up to 58,922,220 shares. This move aims to strengthen the company’s financial position and potentially alter its shareholder structure, depending on the level of participation by existing shareholders. The impact on company control will vary based on shareholder uptake, with significant shareholders potentially increasing their influence if others do not fully subscribe.
Control Bionics Limited has announced a non-renounceable rights issue to raise approximately $2.062 million, underwritten to $1.150 million, to support its growth initiatives. The capital will be used to enhance the commercial rollout of NeuroStrip® and expand the NeuroNode® Only strategy, with ongoing negotiations for distribution partnerships and positive feedback from rehabilitation trials in the US and Australia. Despite slower-than-expected customer acquisition, the company anticipates securing initial contracts by the end of 2025.